Receptor-Independent Metabolic Effects of Thiazolidinediones in Astrocytes

Candan Akar, Sergey Kalinin, Vitaliy Gavrilyuk, Alessandra Spagnolo, Guy Weinberg, and Douglas L Feinstein

Department of Anesthesiology, University of Illinois, Chicago, IL, USA

Abstract: Thiazolidinedione (TZD) agonists of the peroxisome proliferator activated receptor gamma (PPARγ) exert metabolic effects in glial cells. In primary astrocytes, TZDs are cytotoxic and have anti-inflammatory actions; in contrast, in glioma cells TZDs are cytotoxic. Although PPARγ is considered their primary target, TZDs including pioglitazone and troglitazone also bind to a mitochondrial protein MitoNEET; whether their metabolic effects are mediated by activation of PPARγ or MitoNEET is not known. We generated PPARγ null astrocytes by crossing a PPARγ floxed mouse with a transgenic line expressing CRE recombinase under control of the GFAP promoter. PPARγ deficient astrocytes showed reduced lactate production under basal conditions and in response to pioglitazone; however at later times similar levels of lactate were produced. In the presence of troglitazone lactate production was similar in PPARγ null cells as wildtype astrocytes. In astrocytes in which MitoNEET expression was reduced using siRNA, basal lactate production was lower than control cells, however the cells increased lactate production in response to TZDs. When MitoNEET was decreased in the PPARγ null astrocytes, responses to TZDs were reduced compared to non-infected cells. These results indicate that metabolic effects of TZDs are not exclusively mediated via PPARγ, but involve binding to MitoNEET. Real time PCR revealed significantly greater MitoNEET mRNA in glioma cells than astrocytes. Differences in MitoNEET expression or activity could therefore contribute to differential effects of TZDs on astrocyte versus glioma cells.

Keywords: Brain, PPAR, lactate, mitochondria, MitoNEET.

INTRODUCTION

Thiazolidinediones (TZDs) are synthetic compounds used as oral anti-diabetic drugs. TZDs, which include Troglitazone, Pioglitazone, and Rosiglitazone, are agonists of peroxisome proliferator activated receptor gamma (PPARγ) of the PPAR family. PPARγ is the best characterized of the three major isofoms (α, β/δ, and γ), in part due to its therapeutic potential for treatment of diabetes [1] and related consequences such as metabolic syndrome [2]. The glucose-lowering effect of TZDs has been generally assumed to be due to activation of PPARγ which is known to increase transcription of insulin-sensitive genes [3, 4]. In addition to effects on energy and fuel metabolism, several studies report TZD involvement in suppression of cell proliferation, induction of cytotoxicity; and perturbation of mitochondrial function. In these studies the rapid occurrence of agonist induced effects, the lack of correlation between the effects and the affinity for PPARγ, and the inability of antagonists to block the effects suggest PPARγ independent action by TZDs.

In primary cultures of astrocytes, we reported that TZDs cause a rapid increase in glucose consumption and lactate production, associated with an rapid decrease in mitochondrial membrane potential followed by a subsequent hyperpolarization [5]. Similarly, in isolated rat liver, infusion of troglitazone increased lactate production in less than 10 min [6]. Rapid effects on mitochondria were reported with ciglitazone which increased ROS production [7] in astrocytes, and similar effects were observed using 10 to 20 uM pioglitazone or troglitazone in mouse astrocytes and astrocytoma cells [8]. These findings suggest that TZDs may exert direct and rapid effects on mitochondrial respiration leading to changes in glucose metabolism and fuel substrate specificity. Differential effects of TZDs on mitochondrial respiration may account for the selective ability of TZDs to induce toxicity in transformed glial cells.

A possible site of TZD action on mitochondria may be the recently described mitochondrial protein ‘‘mitoNEET’’ [9]. mitoNEET was identified by saturable binding of labeled pioglitazone to crude mitochondrial membranes from bovine brain and several other tissues. The binding of pioglitazone to this protein was specific with half maximal binding occurring between 0.1 and 1 uM. After cross-linking with photolability labeled pioglitazone a 17 kD protein was determined to be the binding site. Consequent purification and proteomic analysis revealed a novel protein containing the sequence Asp-Glu-Glu-Tyr (‘’NEET’’). mitoNEET was also found to be associated with several other mitochondrial proteins, including components of the pyruvate dehydrogenase complex, suggesting a means by which TZD binding to mitoNEET could block pyruvate driven respiration.

In this study we investigated the involvement of mitoNEET in mediation of PPARγ independent metabolic ef-
fects of TZDs. Our data show that knockdown of MitoNEET in astrocytes accomplished by siRNA leads to an increase in lactate production; in contrast, the effects of pioglitazone on lactate production are comparable in PPARγ expressing versus null cells.

**Experimental Procedures**

**Cells**

Primary astrocytes were prepared from cerebral cortices of postnatal day 1 C57BL/6 or PPARγ null mice as described previously [10]. Mouse GL261 glioma cells were grown as previously described [8]. The cells were grown in DMEM containing 25 mM glucose, 10 % FCS and antibiotics (penicillin and streptomycin) by changing the medium every three days for two weeks before using for experiments.

**PPARγ Knockout**

PPARγ conditional astrocyte knockout mice were created as previously described by crossing the PPARγ floxed mice (PPAR f/f, Dr. F. Gonzalez, NIH) with mice having GFAP-driven Cre expression (Cre +/−, Dr. A. Messing, U. Madison). The desired F2 generation mice PPARγ f/f : Cre +/− were crossed to parental PPARγ f/f : Cre +/− mice to generate 50% knockout (KO) and 50% wild type (WT) littermates.

**Infection of Cells with siRNA and Drug Treatment**

Adenovirus particles containing siRNA for mitoNEET were designed and produced from Galapagos Genomics (Mechelen, Belgium). The RNA duplex targeted the 3'end of the mitoNEET mRNA sequence bases 415 5'-AAACCTAAT GCT-3' which spans the stop codon at base 422. The particles were added to DMEM containing 1% FBS. Cells were then treated with the same medium but without adenovirus. Plates were taken from the culture medium at 0 time point then every 2 hrs for assessment of lactate levels. After 6 hrs the medium was removed and 1 ml Trizol reagent (Invitrogen, Carlsbad, CA) / well was added onto the cells. Trizol samples were frozen and kept at -80°C.

**Lactate Assay**

The lactate amounts in samples taken from the culture medium were determined enzymatically using assay kits following manufacturer’s protocol with some modifications. Briefly, 5 ul of sample was incubated with 95 ul of reagent (Trinity Biotech, Bray, Ireland) for 20 min at room temperature and then the absorbance was measured at 540 nm. Lactate amounts were calculated by interpolation from a standard curve of L-lactate in H2O.

**Determination of MitoNEET Knock Down**

Total RNA was isolated from Trizol samples by chloroform extraction and ethanol precipitation. 1 μg of the RNA was converted into cDNA using random hexamer primers, and mRNA levels were determined by quantitative real time-PCR. The reactions were carried out in the presence of SYBRGreen diluted 1:10000 from stock solution (Molecular Probes, Eugene, OR) in Corbett Rotor-Gene real time PCR unit (Corbett Research, Sydney, Australia). The primers used for mouse mitoNEET (Cisd1, accession number NM 134007) were 5'-AAC CTA ATG GAC AGT TGC GAG GCT-3’ forward and 5’-AAG GCC GAT GCC ATG GAT ATG AGA-3’ reverse, which gave a 158 bp product. Relative mRNA concentrations were calculated from the take off point (Ct) of reactions using manufacturer’s software.

**Quantitative PCR**

Real time PCR was used to measure mitoNEET mRNA levels using forward primer 5'-CAA AGC TTA GAC TCT TCAG and reverse primer 5'- GTG CCA TTC TAC GTA AAT CAG which generates a 158 bp product. Values were normalized to levels measured for beta-actin mRNA in the samples using primers 5’ CCT GAA GTA CCC CAT TGA ACA and reverse 5’-CAC ACG CAG CTC ATT GTA GAA. PCR conditions were 35 cycles of denaturation at 94°C for 10s; annealing at 64°C for 15s; and extension at 72°C for 20s on a Corbett Rotorgene Real-Time PCR unit (Corbett, Australia). PCR was done using Taq DNA polymerase (Invitrogen), and contained SYBR Green (SybrGreen110,000x concentrate, diluted 1:10,000; Molecular Probes, Eugene, OR). Relative mRNA concentrations were calculated from the takeoff point of reactions using manufacturer’s software.

**Data Analysis**

Time dependent changes in lactate production between wildtype and PPARγ null cells was compared by 2-way repeated measures ANOVA, and considered significantly different if the time x cell type interaction effects P value was < 0.05.

**Results**

In order to determine whether the metabolic effects of pioglitazone on astrocyte metabolism are mediated through PPARγ we made use of PPARγ conditional astrocyte knockout mice [11]. In wildtype (WT) cells, incubation with pioglitazone or troglitazone induced significant time-dependent increases in lactate production as previously shown [5]. In PPARγ null cells, the baseline production of lactate was slightly, but significantly decreased compared to that in the WT cells (Fig. 1). Between 0 and 4 hr the rate of production was reduced 28% compared to WT cells, however at 6 hr levels were similar. In the presence of pioglitazone, lactate production was also increased in PPARγ null astrocytes although the absolute values were significantly lower than those in the WT cells between 0 and 4 hr, although again at 6 hr levels were comparable. Because of lower production in vehicle treated cells, the magnitude of
The increase due to pioglitazone versus control cells was similar in PPARγ null and WT cells (approximately 80% increase after 2 hr, and 40% increase at 4 and 6 hr). In contrast, lactate production was comparably increased in the two cell types in the presence of troglitazone, which although having a lower affinity than pioglitazone for PPARγ, caused a greater increase in lactate production. These results suggest that metabolic effects of pioglitazone show a partial dependence on the presence of PPARγ, but that this dependence is lost after longer times, or in the presence of a more potent metabolic induce such as troglitazone.

Since pioglitazone can also bind to the mitoNEET protein, we investigated a possible involvement of this protein in mediating the metabolic effects of TZDs (Fig. 2). Infection of primary mouse astrocytes with 10 MOI adenovirus containing siRNA directed against mitoNEET reduced mitoNEET mRNA levels approximately 70% as compared to mock infected cells (Fig. 2A). The reduction in mitoNEET expression was associated with a slight but significant decrease in lactate production versus the non-infected cells (Fig. 2B); at 4 and 6 hr levels were reduced about 30%, compared to non-infected cells. However, treatment with pioglitazone significantly increased lactate production in the control cells as well as the siRNA treated cells; as did incubation with troglitazone. These results suggest that TZD can continue to influence astrocyte metabolism either via effects on residual MitoNEET, or through interactions with PPARγ.

To determine the consequences of combined mitoNEET and PPARγ depletion, we compared the effects of infecting PPARγ null versus WT astrocytes with adenovirus containing siRNA (Fig. 3). In this study, basal production of lactate was similar in the mitoNEET depleted WT and PPARγ null cells; although a slight increase was seen after 6 hr in null cells. In the presence of pioglitazone, lactate production increased over time in both cells types, however there was a significantly lower increase observed in the null cells compared to controls.

---

**Fig. (1). Effect of TZDs on lactate production in PPARγ null astrocytes.**

Astrocytes from PPARγ null (open symbols) and wild type (filled symbols) mice were incubated with 20 μM pioglitazone (circles) or 20 μM troglitazone (triangles in low glucose (5.6 mM) DMEM containing 1% FBS. Control (squares) cultures were incubated with medium plus the equivalent amount of vehicle (DMSO). Lactate levels in the culture media were determined at the indicated time points. The data is the mean ± s.e.m. of n=3 measurements for each point. Two way ANOVA showed that lactate production was significantly different between wild type and PPARγ null cells in the presence of vehicle (P = 0.015) or pioglitazone (P = 0.032); but was not different in the presence of troglitazone.

---

**Fig. (2). Effect of mitoNEET depletion on lactate production in astrocytes.**

Mouse astrocytes were incubated with adenovirus particles (10 MOI / cell), containing siRNA for mitoNEET (open symbols), in DMEM with 1% FBS or with medium alone (filled symbols) for two hours. The medium was then changed to DMEM with 10% FBS. After 72 hrs of incubation the cultures were treated with 20 μM pioglitazone (circles) or troglitazone (triangles) in low glucose (5.6 mM) DMEM containing 1% FBS. Control (squares) cultures were incubated with medium plus the equivalent amount of vehicle. (A) After 6 hr incubation mitoNEET mRNA levels were determined by QPCR, normalized against β-tubulin mRNA levels. (B) Lactate levels were determined in the media at the indicated times. The data is the mean ± s.e.m. of n=3 replicates. The production of lactate in the presence of vehicle was significantly different between control cells and mitoNEET depleted cells (2 way ANOVA, P = 0.0035).
Astrocyte cultures from PPARγ knockout (open symbols) and wild type (filled symbols) mice were incubated with mitoNEET siRNA containing adenovirus particles (10 MOI/cell), then after 72 hr the media was changed and the cells were incubated in low glucose (3.6 mM) DMEM with 1% FCS and 20 μM pioglitazone (circles) or 20μM troglitazone (triangles as in Fig. (3)). Control (squares) cultures were incubated with medium plus the equivalent amount of vehicle. Lactate levels in the media were determined at the indicated time points. The data is the mean ± s.e.m. of n=3 measurements. Lactate production was significantly different between the two cells types in the presence of pioglitazone (2 way ANOVA, P < 0.0001), but not in the presence of troglitazone (P = 0.11).

Fig. (4). MitoNEET mRNA levels in astrocytes versus glioma cells.

Total mRNA was isolated from primary mouse astrocytes and from mouse GL261 glioma cells, converted to cDNA, and relative levels of mitoNEET mRNA determined by quantitative real time PCR. (A) The data is average of 3 measurements for each sample normalized to values for beta-actin mRNAs measured in the same samples. The gel shown in (B) confirms that the PCR products are the correct size generated from astrocytes and glioma cells.

DISCUSSION

In this report we have shown that the ability of two TZDs, pioglitazone and troglitazone to increase lactate production in astrocytes is not fully dependent on PPARγ. Both basal lactate production as well as the increased production due to the presence of pioglitazone were significantly different between control astrocytes and astrocytes in which PPARγ was depleted; however by 6 hr the lactate production was comparable in the two cell types. Furthermore, in the presence of troglitazone virtually identical rates of lactate production were observed. In contrast, depletion of an alternate target of TZDs, the mitoNEET protein present in mitochondria [9], led to a small decrease in the basal production of lactate; although the TZD-dependent increases were similar. Together these findings suggest that both PPARγ as well as mitoNEET contribute to the metabolic effects of TZDs in astrocytes; and this is supported by results showing that depletion of mitoNEET in the PPARγ null astrocytes led to a statistically significant reduction in pioglitazone-dependent lactate production (Fig. 3); and a lesser decrease in the presence of troglitazone.

Metabolic effects of TZDs have been reported for several cell types [12-17], and in many cases these effects occurred relatively rapidly or at TZD doses much higher than their binding affinity for PPARγ, and in some studies, non TZD PPARγ ligands showed little or no metabolic effects. These results raised the possibility that these metabolic effects occurred in a PPARγ independent manner, which are consistent with the current findings in PPARγ null astrocytes.

Alternate sites of action for TZDs have been suggested [18, 19], and recently selective binding to the mitochondrial protein mitoNEET was demonstrated [9]. Using biochemical approaches to identify the binding site for pioglitazone, studies using photoaffinity labeled pioglitazone could only identify a single 17kDa protein that could be specifically crosslinked, which is expressed in the mitochondria; while binding studies using high specific activity radiolabeled pioglitazone Pio showed that MitoNEET was the only protein that could be labeled in whole cell lysates. MitoNEET is a member of a small family of proteins which contain a novel zing finger motif; but contains iron rather than zinc, and contains a 2Fe-2S cluster that is released in a redox and pH dependent manner [20]. MitoNEET has been crystallized and a 1.5A structure determined, which shows that pioglitazone stabilizes the homodimeric form of the protein against release of the 2Fe-2S cluster [21, 22]. The exact function(s) of mitoNeet remain to be clarified, but TZDs including pioglitazone induce a conformational change influencing overall mitochondria redox potential and respiration, and its association with subunits of PDH complex suggests it may be involved in regulation of pyruvate transport or metabolism. Mitochondria isolated from mitoNEET null mice show reduced oxidative capacity [23]. Our findings that when mitoNEET levels are decreased in PPARγ null cells the effect of pioglitazone also decreases suggests an involvement of mitoNEET in mediation of this effect.
In summary, our results demonstrate that metabolic effects of TZDs in primary astrocytes are not fully dependent upon PPARγ activation, and implicate mitoNEET as an additional target for those actions. Initial analysis of mitoNEET expression in primary mouse astrocytes versus glioma cells suggests that mitoNEET is expressed at much higher levels in the tumor cells. This may in part account for the selective ability of TZDs to induce apoptosis in tumor cells [8, 24]. However, further studies where mitoNEET mRNA and protein levels can be reduced to varying degrees, or are completely abolished, are necessary to clarify the relative role of mitoNEET in mediation of TZD effects.

ACKNOWLEDGEMENTS

We thank Jerry Colca (Metabolic Solutions Development) and Patrick Blanner (Pfizer) for providing advice and mitoNEET reagents.

REFERENCES


